India's Cipla falls after Q1 profit miss
BUZZ-India's Cipla falls after Q1 profit miss ** Shares of drugmaker Cipla CIPL.NS slip 2.6% to 1,378.8 rupees
** Co's Q1 consol net profit falls 39.2% to 7.89 billion rupees; misses analyst expectations of 8.7 billion rupees, per LSEG-compiled data
** Co's Q1 total rev from ops beats estimates; rises 2.3% to 71.19 billion rupees
** Stock rated as "Buy" on average; median PT at 1,500 rupees -- LSEG-compiled data
** YTD, stock down ~7.6%
(Reporting by Mridula Kumar in Bengaluru)
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate